azacytosine (Fazarabine or ara-AC); 6-azacytidine (6-aza-CR); 5,6-dihydro-5-azacytidine (dH-aza-CR); N^4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (Capecitabine); N^4-octadecyl-cytarabine; elaidic acid cytarabine; or their derivatives or related analogs.

[0017] Certain embodiments herein provide compositions that are single unit dosage forms comprising a cytidine analog. Certain embodiments herein provide compositions that are non-enteric-coated. Certain embodiments herein provide compositions that are tablets comprising a cytidine analog. Certain embodiments herein provide compositions that are capsules comprising a cytidine analog. In certain embodiments, the single unit dosage forms optionally further contain one or more excipients. In certain embodiments, the tablets optionally further contain one or more excipients. In other embodiments, the capsules optionally further contain one or more excipients. In certain embodiments, the composition is a tablet that effects an immediate release of the API upon oral administration. In other embodiments, the composition is a tablet that effects a controlled release of the API substantially in the stomach. In other embodiments, the composition is a tablet that effects a controlled release of the API substantially in the stomach and the upper intestine. In certain embodiments, the composition is a capsule that effects an immediate release of the API upon oral administration. In other embodiments, the composition is a capsule that effects a controlled release of the API substantially in the stomach. In other embodiments, the composition is a capsule that effects a controlled release of the API substantially in the stomach and the upper intestine. In particular embodiments, the tablet contains a drug core that comprises a cytidine analog, and optionally further contains a coating of the drug core, wherein the coating is applied to the drug core using an aqueous solvent, such as, for example, water, or non-aqueous solvent, such as, for example ethanol.

[0018] Certain embodiments herein provide methods of making formulations of cytidine analogs intended for oral delivery. Further provided are articles of manufacture containing packaging material, an oral formulation of a cytidine analog, and a label that indicates that the formulation is for the treatment, prevention, or management of certain diseases or disorders including, *e.g.*, a cancer, a disorder related to abnormal cell proliferation, a solid tumor, a hematologic disorder, or an immune disorder.

[0018a] In one aspect, there is provided use of a cytidine analog, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and optionally at least one additional therapeutic agent in the manufacture of a medicament for treating a subject having a cancer, wherein the

analog, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is to be administered orally.

[0019] Certain embodiments herein provide methods of using the formulations provided herein to treat, prevent, or manage diseases or disorders including, *e.g.*, cancer, disorders related to abnormal cell proliferation, solid tumors, hematologic disorders, or immune disorders. In certain embodiments, the formulations of cytidine analogs are orally